AmpliPhi Biosciences Corporation, a biotechnology company, focuses on the development of therapies for antibiotic-resistant infections using bacteriophage-based technology. The company is involved in developing AB-SA01 for the treatment of staphylococcus aureus infections; and AB-PA01 for the treatment of pseudomonas aeruginosa infections. AmpliPhi Biosciences Corporation has a collaboration agreement and a license agreement with the University of Leicester; and a collaboration agreement with the Western Sydney Local Health District and the Westmead Institute for Medical Research. The company was formerly known as Targeted Genetics Corporation and changed its name to AmpliPhi Biosciences Corporation in February 2011. AmpliPhi Biosciences Corporation was founded in 1989 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Phone+1-804-8272524
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees31
OptionableNot Optionable
Ampliphi Biosciences (NYSEAMERICAN:APHB) Frequently Asked Questions
What is Ampliphi Biosciences' stock symbol?
Ampliphi Biosciences trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "APHB."
How were Ampliphi Biosciences' earnings last quarter?
Ampliphi Biosciences Corp (NYSEAMERICAN:APHB) released its quarterly earnings results on Thursday, November, 8th. The biotechnology company reported ($0.10) earnings per share for the quarter, topping the consensus estimate of ($0.12) by $0.02. View Ampliphi Biosciences' Earnings History.
When is Ampliphi Biosciences' next earnings date?
What price target have analysts set for APHB?
1 brokers have issued twelve-month price objectives for Ampliphi Biosciences' shares. Their predictions range from $4.00 to $4.00. On average, they expect Ampliphi Biosciences' stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 1,500.0% from the stock's current price. View Analyst Price Targets for Ampliphi Biosciences.
What is the consensus analysts' recommendation for Ampliphi Biosciences?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ampliphi Biosciences in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Ampliphi Biosciences.
Has Ampliphi Biosciences been receiving favorable news coverage?
Press coverage about APHB stock has been trending very positive recently, InfoTrie Sentiment reports. The research firm ranks the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Ampliphi Biosciences earned a daily sentiment score of 3.2 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 4.0 out of 10, indicating that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
Are investors shorting Ampliphi Biosciences?
Ampliphi Biosciences saw a drop in short interest in the month of December. As of December 31st, there was short interest totalling 483,345 shares, a drop of 15.8% from the December 14th total of 574,309 shares. Based on an average daily trading volume, of 514,421 shares, the days-to-cover ratio is presently 0.9 days. Approximately 1.5% of the shares of the stock are short sold. View Ampliphi Biosciences' Current Options Chain.
Who are some of Ampliphi Biosciences' key competitors?
Some companies that are related to Ampliphi Biosciences include 22nd Century Group (XXII), 4d Pharma (DDDD), Abattis Bioceuticals (ATTBF), Abcam (ABC), ABcann Global (ABCN), ABLYNX NV/ADR (ABLX), ABZENA/PAR VTG FPD 0.002 (ABZA), Acasti Pharma (ACST), Acrux (ACR), Actinium Pharmaceuticals (ATNM), Actinogen Medical (ACW), Almirall (LBTSF), Altimmune (ALT), Ampio Pharmaceuticals (AMPE) and Antibe Therapeutics (ATE).
Who are Ampliphi Biosciences' key executives?
Ampliphi Biosciences' management team includes the folowing people:
- Dr. Paul C. Grint, CEO & Director (Age 61)
- Mr. Steven R. Martin, Sr. VP & CFO (Age 58)
- Dr. Igor P. Bilinsky, Sr. VP & COO (Age 46)
- Mr. Michael Scott Salka, Consultant (Age 57)
- Dr. Alexander Gaidamaka, VP of Chemistry, Manufacturing & Control
How do I buy shares of Ampliphi Biosciences?
Shares of APHB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ampliphi Biosciences' stock price today?
One share of APHB stock can currently be purchased for approximately $0.25.
How big of a company is Ampliphi Biosciences?
Ampliphi Biosciences has a market capitalization of $8.07 million. Ampliphi Biosciences employs 31 workers across the globe.
What is Ampliphi Biosciences' official website?
How can I contact Ampliphi Biosciences?
Ampliphi Biosciences' mailing address is 3579 Valley Centre Drive, SAN DIEGO, CA 92130, United States. The biotechnology company can be reached via phone at +1-804-8272524.
MarketBeat Community Rating for Ampliphi Biosciences (NYSEAMERICAN APHB)
MarketBeat's community ratings are surveys of what our community members think about Ampliphi Biosciences and other stocks. Vote "Outperform" if you believe APHB will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APHB will underperform the S&P 500 over the long term. You may vote once every thirty days.
